BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

NCT00904839 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

DRUG: BIBF 1120
DRUG: BIBF 1120
DRUG: mFolfox
DRUG: Bevacizumab
DRUG: mFolfox 6
DRUG: bevacizumab

Sponsor

Boehringer Ingelheim